Direxion Pharma & Medical Bull 3X

The Hill and Definium Therapeutics Host Forum on Psychedelic Therapy Prospects

FDA Accepts Viatris Meloxicam NDA, PDUFA Date Set for Dec 2026

Definium Therapeutics Completes First Patient Dosing in DT120 ODT for Major Depressive Disorder Phase 3 Clinical Trial

Axsome Therapeutics Receives FDA Approval for AUVELITY

Mizuho Raises Axsome Therapeutics Price Target to $310

Enliven Therapeutics released FY2026 Q1 earnings on May 7 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.38 (forecast USD -0.4516)

Definium Therapeutics plans five Phase III studies for DT120 ODT targeting GAD and MDD

Definium Therapeutics Inc Reports Q1 EPS of $(0.71)

Viatris released FY2026 Q1 earnings on May 7 During-Market (EST), actual revenue USD 3.517 B (forecast USD 3.357 B), actual EPS USD 0.15 (forecast USD -0.8445)

Definium Therapeutics released FY2026 Q1 earnings on May 7 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.7099 (forecast USD -0.4953)

Viatris Q1 2026 Revenue and Earnings Per Share Exceed Expectations

Viatris Reports Q1 2026 Earnings and Reiterates Full-Year Guidance

Oppenheimer Increases Holdings in Axsome Therapeutics

Axsome Therapeutics COO sells 4,750 shares after exercising stock options

Mizuho Securities Maintains Buy Rating on Axsome Therapeutics

Needham Raises Axsome Therapeutics Target Price to $267

FactSet lowers Axsome Therapeutics' 2026 EPS forecast

Axsome Therapeutics Reports Strong Q1 2026 Earnings, Core Product Receives FDA Approval for New Indication

Corcept Therapeutics Reports Q1 2025 Earnings

Axsome Therapeutics Reports Strong Q1 Earnings, Ovelity Receives FDA Approval

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

PILL

The Supreme Court declined to hear appeals from six drugmakers against Medicare's drug price negotiations. This decision is projected to save patients $1.5 billion and Medicare $6 billion in the first year. Ongoing legal challenges in lower courts may lead to future Supreme Court reviews.

Bristol Myers Squibb

Johnson & Johnson

Supreme Court rejects drugmakers’ bid to halt Medicare price talks

IBBQ

SBIO

Tigerlily Foundation has partnered with Bristol Myers Squibb to enhance access to clinical trials for young women, particularly women of color. This collaboration aims to reduce barriers to participation and increase awareness through the ONE in a MILLION campaign, which seeks to educate one million women about clinical trials. The initiative emphasizes the importance of diversity in research to improve health equity and treatment effectiveness.

prnewswire

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

iShares US Pharma

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

ProShares Ultra Health Care ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

Ark Genomic Revolution ETF

VG Health

VanEck Biotech ETF

ALPS Medical Breakthrough

Bristol-Myers Squibb Company

09:24 ETTigerlily Foundation Collaborates with Bristol Myers Squibb to Advance Clinical Trial Access and Equity

XOMA

Halper Sadeh LLC is investigating XOMA, Organon & Co., and Veris Residential for potential violations of federal securities laws and breaches of fiduciary duties. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders in proposed transactions. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost. The investigations focus on XOMA's sale for $39.00 per share, Organon's sale for $14.00 per share, and Veris's sale for $19.00 per share, with the firm seeking increased consideration and disclosures on behalf of shareholders.

XOMA Royalty

Organon

Veris Residential

Ligand Pharmac-B

XOMA Corp Pref Share 8.625 Perp 12/15/21

XOMA Pref Share XOMAO 8.375 Perp 04/15/22 B

17:25 ETAre XOMA, OGN, VRE Obtaining Fair Deals for their Shareholders?

LQDA

Liquidia Corporation (NASDAQ:LQDA) has seen an increase in FY2028 EPS estimates by HC Wainwright, now projected at $6.37, up from $5.93. The firm maintains a "Buy" rating with a price target of $67.00. Other analysts have also raised their price targets, with Wells Fargo increasing theirs to $62.00. Liquidia's stock has recently traded up 6.5%, with a market cap of $5.03 billion. The company reported $0.52 EPS for the last quarter, exceeding estimates, and revenue surged 4187.1% year-over-year. Insiders have sold significant shares recently, indicating potential shifts in ownership.

Market Beat

Liquidia Tech

Wells Fargo

Jefferies Financial

Oppenheimer

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Liquidia FY2028 EPS Estimate Increased by HC Wainwright

CRGT

CORT

Corti has launched its Startup Acceleration Program to support healthcare AI startups in overcoming regulatory barriers, particularly in Europe. The program offers access to its clinical-grade AI model, Symphony, which has outperformed OpenAI on HealthBench. With increasing compliance pressures, Corti aims to assist founders in navigating the complex regulatory landscape, providing resources and support to help them scale their innovations. Applications for the program are now open to pre-seed through Series B companies in healthcare and adjacent life sciences.

Cortigent, Inc.

Corcept Therap

OpenAI

12:30 ETCorti steps up its support for the next wave of healthcare startups as OpenAI pushes into the space and others retreat from Europe

AXSM

Axsome Therapeutics is set to launch AUVELITY for Alzheimer’s disease agitation in June, while also expanding its efforts in major depressive disorder (MDD). The company has increased its sales force to 630 representatives and reports 86% payer access for AUVELITY in MDD. The drug's unique mechanism targets NMDA and sigma-1, differentiating it from existing treatments. Axsome anticipates that 80% of prescriptions will be covered under Medicare Part D, with a focus on long-term care facilities. The company aims to leverage synergies between Alzheimer’s agitation and MDD treatments.

Axsome Therap

Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch

Liquidia Corp (LQDA) reported strong Q1 results with earnings of 52 cents per share and sales of $132.865 million, surpassing analyst expectations. Following this, analysts raised their price targets: Wells Fargo's Benjamin Burnett increased it from $51 to $62, while HC Wainwright's Andrew S. Fein raised it from $55 to $67. Liquidia shares rose 3.1% to $54.80 after the announcement.

benzinga_article

These Analysts Boost Their Forecasts On Liquidia After Upbeat Q1 Results

600276

Bristol Myers Squibb (BMS) and Hengrui Pharma have formed a global strategic collaboration and licensing agreement covering 13 early-stage programs in oncology, hematology, and immunology. Announced on May 12, 2026, the deal includes a $950 million payment structure, with BMS paying $600 million upfront. The collaboration aims to leverage BMS's global capabilities and Hengrui's discovery platforms to accelerate the development of new therapies. BMS will hold exclusive rights to Hengrui-originated assets outside certain territories, while Hengrui will manage proof-of-concept activities and may co-develop selected assets.

Pharmexec

Hengrui Pharma

HENGRUI PHARMA

<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>

Tempus AI Inc. and Bristol Myers Squibb Co. have announced a collaboration to enhance clinical trial design using AI and real-world data across oncology and Alzheimer's programs. The initiative aims to improve drug development strategies by analyzing multimodal patient records to identify suitable patient populations and validate control groups. This partnership builds on existing efforts to address care gaps in advanced lung cancer. Tempus AI shares fell 0.96% to $45.88, while Bristol Myers Squibb shares rose 0.34% to $56.58.

Tempus AI

S&P 500

Taiwan Semiconductor

Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts

Axsome Therapeutics has received FDA approval for AUVELITY, the first treatment for agitation associated with Alzheimer's disease, creating a new commercial opportunity. The stock is currently priced at $216.47, with a 21.5% increase over the past month. Analysts suggest the stock is trading below its fair value, indicating potential upside. Investors should monitor prescription uptake and analyst price targets, while being aware of future safety communications regarding AUVELITY. This approval may enhance Axsome's position in neuropsychiatric treatments and influence revenue expectations in central nervous system disorders.

Simplywall

Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions

Direxion Pharma & Medical Bull 3X(PILL.US)